UCLA’s Beth Karlan receives IGCS’s lifetime achievement award

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Physician-scientist Beth Karlan, professor of obstetrics and gynecology in the David Geffen School of Medicine at UCLA and director of cancer population genetics at the UCLA Jonsson Comprehensive Cancer Center, has received the Lifetime Achievement Award from the International Gynecologic Cancer Society for her contributions to gynecologic cancer research and clinical practice. 

The award is bestowed annually.  

Karlan is being recognized for advancing the understanding of hereditary cancers and molecular drivers of ovarian cancer and her commitment in seeking better ways to prevent and eradicate deadly cancers.   

In the laboratory, Karlan has identified subtype-specific biomarkers for early detection, prognostication and personalized therapies. She established a human tissue biorepository to collect fresh frozen tissue, serum, and germline DNA from women with ovarian and other gynecologic cancers in order to study cancers’ biologic differences and develop improved treatments. 

This resource has been used in national and international collaborations including The Cancer Genome Atlas project, Consortium of Investigators of Modifiers of BRCA1/2 and Ovarian Cancer Association Consortium — partnerships that have helped to shape current standards of care for gynecologic oncology. 

She is also a co-PI on a national effort using a digital platform to implement population-based genetic testing for BRCA1 and BRCA2 mutations. 

The award will be presented to Karlan at the IGCS annual global meeting in Rome Sept. 1.

Table of Contents

YOU MAY BE INTERESTED IN

In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL). 
Over the past three decades, cancer genetics has transformed precision oncology. Germline testing has advanced from single-gene Sanger sequencing to parallel sequencing of hundreds of genes, while tumor (somatic) testing has expanded with the rise of targeted therapies based on point mutations, copy number changes and other alterations. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login